Opaleye Management Inc. Relmada Therapeutics, Inc. Transaction History
Opaleye Management Inc.
- $390 Million
- Q2 2024
A detailed history of Opaleye Management Inc. transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 600,000 shares of RLMD stock, worth $1.44 Million. This represents 0.46% of its overall portfolio holdings.
Number of Shares
600,000
Previous 759,000
20.95%
Holding current value
$1.44 Million
Previous $3.53 Million
48.99%
% of portfolio
0.46%
Previous 0.86%
Shares
4 transactions
Others Institutions Holding RLMD
# of Institutions
88Shares Held
13.5MCall Options Held
85.8KPut Options Held
42.8K-
Vanguard Group Inc Valley Forge, PA1.26MShares$3.02 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.23MShares$2.96 Million0.12% of portfolio
-
Vestal Point Capital, LP New York, NY1.2MShares$2.88 Million0.27% of portfolio
-
Acadian Asset Management LLC Boston, MA1.19MShares$2.86 Million0.01% of portfolio
-
Franklin Resources Inc San Mateo, CA1.01MShares$2.43 Million0.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $68.7M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...